{"id":"W2512436288","doi":"10.1136/annrheumdis-2016-209709","title":"Ixekizumab, an interleukin-17A specific monoclonal antibody, for the treatment of biologic-naive patients with active psoriatic arthritis: results from the 24-week randomised, double-blind, placebo-controlled and active (adalimumab)-controlled period of the phase III trial SPIRIT-P1","year":2016,"lang":"en","type":"article","venue":"Annals of the Rheumatic Diseases","topic":"Spondyloarthritis Studies and Treatments","field":"Medicine","cited_by":568,"is_retracted":false,"has_abstract":true,"ca_institutions":"University of Toronto","funders":"UCB Pharma; Genentech; Chugai Pharmaceutical; Mitsubishi Tanabe Pharma Corporation; Santen; Pfizer; Abbott Japan; Novo Nordisk; Sanofi; GlaxoSmithKline; Amgen; Celgene; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Ixekizumab; Medicine; Placebo; Psoriatic arthritis; Adalimumab; Internal medicine; Psoriasis; Adverse effect; Immunology; Arthritis; Secukinumab; Pharmacology; Gastroenterology; Rheumatoid arthritis; Pathology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004554152,0.0007791095,0.001607413,0.0002953207,0.0002215486,0.0005889932,0.0006509375,0.0008776681,0.002951708],"category_scores_gemma":[0.001806391,0.0003636374,0.001274378,0.0003021159,0.000758361,0.0005687209,0.0002925249,0.001870256,0.0004338471],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0004182344,"about_ca_system_score_gemma":0.0008070132,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0004329623,"about_ca_topic_score_gemma":0.0007966647,"domain_scores_codex":[0.9988835,0.0007518411,0.0000892819,0.00009275026,0.0001149586,0.00006769672],"domain_scores_gemma":[0.9989053,0.0003280611,0.000326759,0.00008245892,0.00007209624,0.0002853325],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.8806353,0.01222106,0.004223513,0.001516537,0.001683457,0.00005691347,0.0001116219,0.0005702895,0.01211756,0.0001079241,0.001428648,0.08532713],"study_design_scores_gemma":[0.8459163,0.1410078,0.009150138,0.00004925816,0.0007363464,0.00009644969,0.00002022094,0.0003338081,0.0015114,0.00007075043,0.001093767,0.00001369184],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9817965,0.01278587,0.0009976393,0.000573391,0.0002333876,0.001742969,0.0007977682,0.00007572992,0.0009967196],"genre_scores_gemma":[0.9851344,0.006391077,0.00269752,0.0008344778,0.0004520236,0.001394856,0.001591803,0.00001961376,0.001484287],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.004554152,"threshold_uncertainty_score":0.02408493,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.05109430224959261,"score_gpt":0.3221726779938731,"score_spread":0.2710783757442805,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}